MedDRA Preferred Term Reaction	Count	%Rpts
SWOLLEN TONGUE	65	0.4%
VENTRICULAR FIBRILLATION	65	0.4%
OXYGEN SATURATION DECREASED	65	0.4%
ABDOMINAL DISTENSION	64	0.4%
EYE PAIN	64	0.4%
ENCEPHALOPATHY	64	0.4%
DRY MOUTH	64	0.4%
BLOOD GLUCOSE DECREASED	63	0.4%
HAEMATOMA	63	0.4%
OROPHARYNGEAL PAIN	63	0.4%
HYPOPHAGIA	62	0.4%
PULMONARY EMBOLISM	62	0.4%
TENDON INJURY	62	0.4%
PROTHROMBIN LEVEL DECREASED	62	0.4%
BLOOD POTASSIUM DECREASED	61	0.4%
VISUAL ACUITY REDUCED	61	0.4%
BRONCHOSPASM	60	0.4%
SKIN EXFOLIATION	60	0.4%
PANCREATITIS	60	0.4%
BONE PAIN	59	0.4%
CHROMATURIA	59	0.4%
RESPIRATORY ARREST	59	0.4%
RESPIRATORY DISORDER	59	0.4%
MENISCUS LESION	59	0.4%
ABNORMAL DREAMS	58	0.4%
RESPIRATORY DISTRESS	58	0.4%
NO THERAPEUTIC RESPONSE	58	0.4%
CLOSTRIDIAL INFECTION	57	0.4%
CRYING	57	0.4%
CARDIAC DISORDER	56	0.4%
DIALYSIS	56	0.4%
DYSARTHRIA	56	0.4%
HEPATOCELLULAR INJURY	56	0.4%
DRUG LEVEL ABOVE THERAPEUTIC	55	0.4%
FEAR	55	0.4%
INJECTION SITE PRURITUS	55	0.4%
INFLUENZA LIKE ILLNESS	54	0.4%
THINKING ABNORMAL	54	0.4%
PHOTOSENSITIVITY REACTION	54	0.4%
MUSCLE DISORDER	54	0.4%
DEEP VEIN THROMBOSIS	53	0.4%
GAMMA-GLUTAMYLTRANSFERASE INCREASED	53	0.4%
ABDOMINAL DISCOMFORT	52	0.4%
ALOPECIA	52	0.4%
CANDIDIASIS	52	0.4%
MUSCLE TIGHTNESS	52	0.4%
SENSORY DISTURBANCE	52	0.4%
MOBILITY DECREASED	52	0.4%
AGRANULOCYTOSIS	51	0.3%
SLEEP DISORDER	51	0.3%
WEIGHT INCREASED	51	0.3%
DERMATITIS EXFOLIATIVE	51	0.3%
HEPATIC ENZYME INCREASED	51	0.3%